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Received October 9, 2012; accepted April 3, 2013AbstractBackground: Although there were some reports predicting postoperative morbidity and mortality in patients undergoing liver transplantation,
most of them studied deceased-donor liver transplantation (DDLT). In this context, we performed this study to predict early mortality after liver
transplantation from preoperative variables in both living-donor liver transplantation (LDLT) and DDLT.
Methods: We retrospectively reviewed the medical charts of 159 patients undergoing liver transplantation (LDLT, n ¼ 103; DDLT, n ¼ 56).
Then, we identified the factors that independently predicted 30-day mortality using multivariable logistic regression models.
Results: The 30-day mortality and 1-year mortality for DDLT versus LDLT were 30% versus 6% and 39% versus 11%, respectively. In
multivariate logistic regression analysis, pretransplant hepatic encephalopathy (odds ratio, 5.594; 95% confidence interval, 1.110e28.194;
p ¼ 0.037) in patients with DDLT and serum creatinine (odds ratio, 4.883; 95% confidence interval, 1.296e18.399; p ¼ 0.019) in patients with
LDLT were the independent risk factors for a composite of 30-day mortality.
Conclusion: In conclusion, hepatic encephalopathy in DDLT and serum creatinine level in LDLTwere the significant pretransplant variables that
were related with early death after LT.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Liver transplantation (LT) for patients with hepatocellular
carcinoma, cirrhosis, and fulminant hepatic failure is fairly
common. However, this operation is not without riskdit
carries a 5e10% incidence of 30-day mortality.1 Identification
of pretransplant risk factors that predict early mortality is
important for postoperative management. It has been known* Corresponding author. Dr. Shin Ok Koh, Department of Anesthesiology
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http://dx.doi.org/10.1016/j.jcma.2013.09.003that accuracy rates for pretransplant MELD (Model for End-
stage Liver Disease) score and ChildePugh classification are
low as predictors of 3-month postoperative mortality.2,3 The
ChildePugh score has been used to assess the prognosis of
patients with liver cirrhosis. Although it was originally used to
predict mortality during surgery, it is now used to determine
the prognosis, as well as the required strength of treatment and
the necessity of liver transplantation. However, a limitation of
the classification is that each variable is given the same
weight. Multivariate analysis showed that the impacts of the
different predictive factors on mortality were different.4
Giving the same weight to different variables resulted in
overestimating or underestimating their actual impact. In
previously reported studies, the predictive values of survival
explained by ChildePugh scores were less than 50%.5 Thehinese Medical Association. All rights reserved.
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survival after transjugular intrahepatic portosystemic shunt,4
has been also used for predicting pretransplant survival, but
its usefulness as a model to predict survival following LT is
still controversial.6,7 Although there had been some reports
predicting postoperative morbidity and mortality in patients
undergoing liver transplantation including ChildePugh clas-
sification, pre-LT renal insufficiency, malnutrition, technically
complex surgery indexes,8 and the MELD,9 most of them have
been studied in deceased-donor liver transplantation (DDLT).
The purpose of this study was to assess the predictive
variables for posttransplant mortality and investigate the pre-
dictors of mortality for patients with living- and deceased-
donor LT.
2. Methods2.1. ParticipantsWe retrospectively reviewed the medical charts of 159
consecutive LTs (living donor, n ¼ 103; deceased donor,
n ¼ 56) that had been performed in our institute from March
2007 to October 2010. Patients were excluded if they had any
history of advanced heart or lung conditions or aged <20
years.2.2. Anesthesia and operative proceduresOn arrival at the operating room, standard monitoring such
as lead II and V5 of electrocardiography, arterial blood pres-
sure, pulse oximetry, bispectral index, and cerebral oximetry
were applied. A pulmonary artery catheter (Swan-Ganz
CCOmbo CCO/SvO2; Edwards Lifesciences LLC, Irvine, CA,
USA) was inserted via the right internal jugular vein, and we
monitored continuous cardiac output and mixed venous oxy-
gen saturation and pulmonary arterial pressure. Anesthesia
was induced with intravenous propofol, remifentanil, and
atracurium, and then maintained with desflurane, remifentanil,
and atracurium. Intravascular volume replacement was
managed with crystalloid and colloid solutions to maintain the
pulmonary capillary wedge pressure between 8 mmHg and
14 mmHg. The central blood temperature, which was
measured using a pulmonary artery catheter, was maintained
at about 36 C with a warm mattress, a forced warm air
blanket, and fluid warmer as necessary. During the surgical
procedure, the mean arterial pressure was maintained above
70 mmHg with dopamine, norepinephrine, vasopressin, or
epinephrine infusion. Allogenic-packed red blood cells were
transfused when the hematocrit level was under 25%
throughout the study period. Surgical procedures proceeded in
the standard order used at our clinics. After mobilization of the
recipient liver, the native liver was removed. Whole-size
DDLT and right-lobe living-donor LT (LDLT) was per-
formed in each group. For DDLT, donor age under 60 years
and donation prior to cardiac death with Asian race without
hepatic problems were selected.10 After reperfusion, several
anastomoses, hemostases, and closures were performed. Allpatients were transferred to the intensive care unit (ICU)
after surgery. They received standardized ICU care at the
discretion of the ICU staff according to the standard ICU
protocols. Criteria for weaning from ventilatory support
included an appropriate sensorium, hemodynamic stability
(cardiac index, >2.2 L/min/m2; pulmonary capillary wedge
pressure, >60 mmHg; pulmonary capillary wedge pressure,
<20 mmHg; and no significant arrhythmias), PaO2/FiO2>200,
minimal operation site drainage, no signs of hepatic failure or
graft dysfunction, and temperature>35.5C. Discharge criteria
from the ICU were as follows: stabilized patient’s clinical
status without the need for ICU monitoring and care (including
no further requirement for either inotropic or vasoactive
agents), and no plan for further active intervention.2.3. Statistical analysisWe identified factors that were independently associated
with 30-day mortality with multivariate logistic regression
models. The factors considered were age, sex, and components
of ChildePugh classification [hepatic encephalopathy (HE),
ascites, total bilirubin, international normalized ratio (INR),
serum albumin] and MELD score (serum creatinine, INR, total
bilirubin),11 as well as donor factors (age, sex, cold ischemic
time, graft size in the LDLT, bile duct variation, macro-
vesicular steatosis, lymphocyte crossmatching).
Data were analyzed with SPSS version 18 (SPSS, Inc.,
Chicago, IL, USA) and expressed as mean  SD or number of
patients (%). Continuous variables were analyzed by inde-
pendent t tests. Categorical data were analyzed with the Chi-
square test. To determine the preoperative mortality predic-
tor, an initial univariate analysis was used with logistic
regression. Variables that showed p <0.1 by univariate anal-
ysis were included in the multivariable logistic regression
model. A p value of <0.05 was considered statistically
significant.2.4. Ethics statementThis study was approved by the institutional review board
of our hospital (Ref: 4-2010-0671).
3. Results3.1. Characteristics of patients and mortalityPatients’ characteristics and perioperative data are shown in
Table 1. The overall 30-day mortality and 1-year mortality
were 14% and 21%, respectively. The periodic difference of
mortality from March 2007 to October 2010 was not found
retrospectively. More patients with fulminant hepatic failure
were in the DDLT group than in the LDLT group (18% vs. 4%,
p ¼ 0.006). The 30-day mortality (30% vs. 6%, p <0.001) and
1-year mortality (39% vs. 11%, p <0.001) were higher in
DDLT than in LDLT. Patients with fulminant hepatic failure
had higher 30-day mortality (43% vs. 12%, p ¼ 0.007) and 1-
year mortality (57% vs. 17%, p ¼ 0.002) than patients without
Table 1
Patients’ characteristics and mortality.
DDLT (n ¼ 56) LDLT (n ¼ 103) p
Age (y) 49  11 53  9 0.031*
Sex (M/F) 39:17 83:20 0.070
Weight (kg) 70  12 66  12 0.041*
Height (cm) 167  8 165  12 0.361
Cause of LT
Fulminant hepatic failure 10 (18) 4 (4) 0.006*
Hepatitis B 33 (59) 58 (68) 0.298
Hepatocellular carcinoma 3 (5) 17 (17) 0.047*
MELD score 24  12 15  9 <0.001*
ChildePugh class C 36 (64) 29 (28) <0.001*
HE grade 3 23 (41) 16 (16) 0.001*
Ascites grade 3 21 (38) 28 (27) 0.115
Total bilirubin (mg/dL) 2.3  0.9 1.7  0.9 <0.000*
Albumin (g/dL) 3.1  0.7 3.0  0.6 0.852
INR 1.8  0.9 1.3  0.6 0.000*
Serum creatinine (mg/dL) 1.4  1.3 1.0  0.5 0.022*
30-d mortality 17 (30) 6 (6) <0.001*
1-y mortality 22 (39) 11 (11) <0.001*
Data are presented as mean  SD or n (%).
*Significant finding.
DDLT ¼ deceased-donor liver transplantation; HE ¼ hepatic encephalopathy;
INR ¼ international normalized ratio; LDLT ¼ living-donor liver trans-
plantation; MELD ¼ Model for End-stage Liver Disease. HE grade:
1 ¼ absent; 2 ¼ mild; 3 ¼ severe. Ascites grade: 1 ¼ absent;
2 ¼ mildemoderate; 3 ¼ severe/refractory.
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higher in the DDLT group than in the LDLT group (24  12
vs. 15  9, p ¼ 0.001). The ChildePugh class C was 64% in
the DDLT group and 28% in the LDLT group ( p <0.001).3.2. Mortality predictors in the DDLT and LDLT groupsIn the analysis of the scoring system, ChildePugh classi-
fication [odds ratio (OR), 15.200; 95% confidence interval
(CI), 1.833e126.079; p ¼ 0.023] but not the MELD score inTable 2
Logistic regression analysis for predictors of composite mortality in DDLT.
Univariate regressio
OR 95% CI
Recipient factors
Age 0.935 0.882e0.992
Female sex 0.615 0.167e2.266
Weight 1.018 0.970e1.068
HE grade 3 13.533 3.209e57.078
Ascites grade 3 1.800 0.470e6.898
Total bilirubin 1.070 1.019e1.124
Albumin 1.753 0.742e4.135
INR 3.820 1.581e9.232
Serum creatinine 1.260 0.835e1.900
Donor factors
Female sex 0.982 0.253e3.806
Cold ischemic time 4.986 1.184e20.997
Degree of macrovesicular steatosis 1.029 0.970e1.090
Positive lymphocyte crossmatching 0.000 0.000e
* Significant finding.
CI ¼ confidence interval; DDLT ¼ deceased-donor liver transplantation; HE ¼ he
HE grade: 1 ¼ absent; 2 ¼ mild; 3 ¼ severe. Ascites grade: 1 ¼ absent; 2 ¼ milthe DDLT group, and MELD score (OR, 1.070; 95% CI,
1.024e1.119; p ¼ 0.003) but not the ChildePugh classifica-
tion in the LDLT group were significant in the univariate
analysis.
The logistic analysis of each component of ChildePugh
classification and MELD score are demonstrated in Tables 2
and 3. In the univariate analysis for 30-day mortality pre-
dictors, age, pretransplant HE, total bilirubin, INR, and cold
ischemic time were the significant risk factors, and in the
multivariable logistic regression analysis of these variables,
only HE was an independent risk factor for a composite of
mortality following DDLT (Table 2). In the LDLT group,
pretransplant HE, total bilirubin, serum creatinine, and mac-
rovesicular steatosis of donor liver were the significant risk
factors in the univariate analysis, and in the multivariable lo-
gistic regression analysis, only serum creatinine was an in-
dependent risk factor for a composite of mortality (Table 3).3.3. Intra- and postoperative coursesThe intra- and postoperative courses are demonstrated in
Table 4. The total anesthesia time, operative time, and anhe-
patic time were longer in the LDLT group than in the DDLT
group. The amount of operative-site drainage, including as-
cites and blood, was higher in the DDLT group, and more
transfusion was required in DDLT than in LDLT. The duration
of intubation time and stay in ICU were longer in DDLT than
in LDLT.
4. Discussion
In our study, HE after DDLT and serum creatinine level
after LDLT were the only pretransplant variables that were
significantly related to early death. Pretransplant MELD score
was higher and more ChildePugh class C patients were found
following DDLT compared with LDLT. These differences inn Multivariate regression
p OR 95% CI p
0.026 0.986 0.915e1.063 0.715
0.465
0.468
<0.001 5.594 1.110e28.191 0.037*
0.391
0.007 1.005 0.924e1.093 0.913
0.200
0.003 1.964 0.476e8.103 0.351
0.270
0.979
0.028 3.265 0.589e18.091 0.176
0.345
0.998
patic encephalopathy; INR ¼ international normalized ratio; OR ¼ odds ratio.
demoderate; 3 ¼ severe/refractory.
Table 3
Logistic regression analysis for predictors of composite mortality in LDLT.
Univariate regression Multivariate regression
OR 95% CI p OR 95% CI p
Recipient factors
Age 0.954 0.875e1.039 0.279
Weight 0.989 0.931e1.050 0.712
HE grade 3 6.462 1.176e35.497 0.032 4.270 0.442e41.298 0.210
Ascites grade 3 0.741 0.261e2.104 0.574
Total bilirubin 1.058 0.990e1.131 0.098 0.998 0.906e1.100 0.974
Albumin 0.716 0.221e2.319 0.577
INR 2.061 0.844e5.036 0.113
Serum creatinine 4.286 1.613e11.386 0.004 4.883 1.296e18.399 0.019*
Donor factors
Donor age 1.010 0.949e1.074 0.764
Female sex 0.508 0.102e2.531 0.408
Cold ischemic time 1.006 0.362e2.798 0.991
Graft size 1.002 0.996e1.007 0.560
Degree of macrovesicular steatosis 1.125 1.003e1.265 0.044 1.161 0.991e1.361 0.064
Positive lymphocyte crossmatching 1.208 0.135e10.788 0.865
* Significant finding.
CI ¼ confidence interval; HE ¼ hepatic encephalopathy; INR ¼ international normalized ratio; LDLT ¼ living-donor liver transplantation; OR ¼ odds ratio. HE
grade: 1 ¼ absent; 2 ¼ mild; 3 ¼ severe. Ascites grade: 1 ¼ absent; 2 ¼ mildemoderate; 3 ¼ severe/refractory.
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prognosis after LT including poor ICU course and higher
mortality.
In Asia, the incidence of hepatitis B virus-related cirrhosis
and carcinoma is high.12 However, for various social and
cultural reasons, deceased-donor organ allocation remains
below 5 per 1 million population per year in Asia.13 With the
limited supply of deceased donors, the large number of pa-
tients who are on the waiting list for LT represents aTable 4
Intraoperative data and postoperative courses.
DDLT (n ¼ 56) LDLT (n ¼ 103) p
Intraoperative
Anesthesia time (h) 11  2 14  2 <0.001*
Operative time (h) 9  2 13  2 <0.001*
Anhepatic time (h) 1.5  0.4 2.0  0.6 <0.001*
Infused fluid (mL/h) 1251  762 1026  483 0.628
RBC transfusion (mL) 2000 (1000e3750) 1250 (500e2750) 0.055
Estimated blood loss
(mL)
6200 (3600e10,650) 4785 (2887e9675) 0.131
Urine output (mL/h) 130  114 145  120 0.021*
Postoperative ICU course
RBC transfusion (mL) 1750 (750e3250) 750 (500e1000) 0.001*
Op-site drainage (mL) 9172 (3506e16,465) 4277 (2295e8400) 0.007*
Urine output (mL/h) 66  50 106  61 <0.001*
Total admission (d) 43  36 47  37 0.500
ICU admission (d) 11  9 8  7 0.020*
Intubation time (h) 119  109 60  86 0.001*
Reoperation for any
cause, n (%)
7 6 0.223
Re-endotracheal
intubation, n (%)
7 8 0.398
Data are presented as mean  SD, median (interquatile range), or n (%).
*Significant finding.
DDLT ¼ deceased donor liver transplantation; ICU ¼ intensive care unit;
LDLT ¼ living donor liver transplantation; RBC transfusion ¼ packed red
blood cell transfusion.problematic issue in Asia. Overall, LDLT accounts for more
than 90% of all LTs in Asia compared with less than 5% in the
United States.14
LDLT may reduce the waiting time and enable the optimal
timing of transplantation compared with DDLT especially in
patients with tumors, cholestatic diseases, or blood type O, and
those who require retransplantation. Also, normal liver func-
tion with short ischemic time improves the success rate with
respect to primary nonfunction of graft.15 However, the sur-
gical procedures involved in adult LDLT are more complex
than those of whole-size DDLT because a partial graft has
smaller and shorter hepatic arteries and bile duct. Thus, the
incidence of biliary complications increases with partial grafts
and the small-for-size syndrome could be problematic in
LDLT.16 Despite the differences between LDLT and DDLT
mentioned above, there has been no study that evaluated the
mortality predictors in both LDLT and DDLT. Hence, we
analyzed both LDLT and DDLT for mortality prediction.
This study identified pretransplant HE grade 3 as a unique
predictor of survival. HE is a serious complication of
decompensated cirrhosis that manifests as a wide range of
neuropsychological clinical findings ranging from minimal
cognitive dysfunction to coma.17 Liver allograft allocation
changed in the United States with the implementation of the
MELD-based system in 2002. As a result, HE is not used as a
criterion to prioritize patients on the transplantation waiting
list. In a previous large cohort study, the episode of HE was
not an independent factor that influenced short-term survival
in patients with cirrhosis.18 However, little is known about the
effect of encephalopathy on posttransplant morbidity and
mortality. The risk of post-LT neurological complication is
greater in patients who have pretransplant HE after DDLT.19
Also, it has been observed that individuals with severe pre-
transplant HE have experienced more prolonged posttrans-
plant altered mental status and infectious complications and
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study, HE was a predictor of survival following only DDLT,
but not LDLT. This might be attributable to the difference in
the number of HE cases between the two groups. Although
24% of patients experienced HE prior to transplantation in the
LDLT group, 52% of patients experienced HE in the DDLT
group, and the overall incidence of severe HE was 41% in the
DDLT group and 16% in the LDLT group ( p ¼ 0.001).
In our study, pretransplant serum creatinine was a predictor
of short-term survival following LDLT, but not DDLT. Serum
creatinine is one of the key components of a MELD scoring
system. One study reported the impact of individual MELD
components, especially creatinine, on survival benefit after
DDLT. The investigators concluded that pretransplant serum
creatinine was an important predictor of LT survival benefit
independent of the MELD score of 15e17 or 24e40.21 How-
ever, in certain categories of MELD score, patients with higher
serum creatinine levels meant lower bilirubin levels and/or INR
in comparison with their counterparts with lower serum
creatinine levels. By contrast, there was a report that pre-
transplant renal function had no effect on patient survival after
DDLT.22 We could not find any report that evaluated the cor-
relation between preoperative renal function and postoperative
survival in LDLT. Furthermore, we could not exclude the
possibility of overestimation of renal function in the LDLT
group compared with the DDLT group. Creatinine is influenced
by sex, age, and muscle mass, and many patients with cirrhosis
have muscle wasting. In our analysis, age was significantly
high ( p ¼ 0.031) and body weight was significantly lower in
the LDLT group than in the DDLT group ( p ¼ 0.041). Despite
the absence of the periodic difference of the mortality rate
during the study period, the overall mortality rate was higher in
our institute than that in previous reports (8.2%).12 In this
study, we included fulminant hepatic failure and patients with
higher severity, especially in the DDLT group. So the mortality
rate might be comparable with that in previous reports.
In conclusion, pretransplant HE in the DDLT group and
serum creatinine level in the LDLT group might be potential
markers predicting 30-day mortality.
References
1. Scientific Registry of Transplant Recipients. Available at www.srtr.org
[accessed 1.4.10].
2. Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C,
et al. Pretransplant model to predict posttransplant survival in liver
transplant patients. Ann Surg 2002;236:315e23.
3. Desai NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW,
et al. Predicting outcome after liver transplantation: utility of the modelfor end-stage liver disease and a newly derived discrimination function.
Transplantation 2004;77:99e106.
4. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A
model to predict poor survival in patients undergoing transjugular intra-
hepatic portosystemic shunts. Hepatology 2000;31:864e71.
5. Christensen E. Prognostic models including the ChildePugh, MELD and
Mayo risk scoresdwhere are we and where should we go? J Hepatol
2004;41:344e50.
6. Nagler E, Van Vlierberghe H, Colle I, Troisi R, de Hemptinne B. Impact
of MELD on short-term and long-term outcome following liver trans-
plantation: a European perspective. Eur J Gastroenterol Hepatol
2005;17:849e56.
7. Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al.
MELD and prediction of post-liver transplantation survival. Liver Transpl
2006;12:440e7.
8. Bilbao I, Armadans L, Lazaro JL, Hidalgo E, Castells L, Margarit C.
Predictive factors for early mortality following liver transplantation. Clin
Transplant 2003;17:401e11.
9. Santori G, Andorno E, Antonucci A, Morelli N, Bottino G, Mondello R,
et al. Potential predictive value of the MELD score for short-term mor-
tality after liver transplantation. Transplant Proc 2004;36:533e4.
10. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD,
DebRoy MA, et al. Characteristics associated with liver graft failure: the
concept of a donor risk index. Am J Transplant 2006;6:783e90.
11. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, et al.
3-month and 12-month mortality after first liver transplant in adults in
Europe: predictive models for outcome. Lancet 2006;367:225e32.
12. Kwon CHD, Lee SK, Ha J. Trend and outcome of Korean patients
receiving overseas solid organ transplantation between 1999 and 2005. J
Korean Med Sci 2011;26:17e21.
13. de Villa VH, Lo CM, Chen CL. Ethics and rationale of living-donor liver
transplantation in Asia. Transplantation 2003;75(3 Suppl):S2e5.
14. de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in
Asia. Oncologist 2007;12:1321e31.
15. Lee SG. Living-donor liver transplantation in adults. Br Med Bull
2010;94:33e48.
16. Testa G, Malago´ M, Valentı´n-Gamazo C, Lindell G, Broelsch CE. Biliary
anastomosis in living related liver transplantation using the right liver
lobe: techniques and complications. Liver Transpl 2000;6:710e4.
17. Stewart CA, Malinchoc M, KimWR, Kamath PS. Hepatic encephalopathy
as a predictor of survival in patients with end-stage liver disease. Liver
Transpl 2007;13:1366e71.
18. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM,
Kosberg CL, et al. A model to predict survival in patients with end-stage
liver disease. Hepatology 2001;33:464e70.
19. Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preop-
erative overt hepatic encephalopathy on neurocognitive function after liver
transplantation. Liver Transpl 2009;15:184e92.
20. Brandman D, Biggins SW, Hameed B, Roberts JP, Terrault NA. Pre-
transplant severe hepatic encephalopathy, peritransplant sodium and post-
liver transplantation morbidity and mortality. Liver Int 2012;32:158e64.
21. Sharma P, Schaubel DE, Guidinger MK, Merion RM. Effect of pre-
transplant serum creatinine on the survival benefit of liver transplantation.
Liver Transpl 2009;15:1808e13.
22. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM,
Husberg BS. Impact of pretransplant renal function on survival after liver
transplantation. Transplantation 1995;59:361e5.
